IL6 and breast cancer: This link between high-risk IL-6 promoter genotypes and treatment resistance can at least partly be explained by IL-6’s known action of inducing the aromatase enzyme, particularly in the breast cancer microenvironment, increasing local levels of estrogens in an autocrine fashion and thereby promoting growth and survival27,28.